Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingWages, Salaries and Other
Ratios

Ptc Therapeutics (PTCT) Accumulated Depreciation & Amortization: 2012-2024

  • Ptc Therapeutics' Accumulated Depreciation & Amortization fell 34.94% to $33.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $149.2 million, marking a year-over-year increase of 11.43%. This contributed to the annual value of $33.4 million for FY2024, which is 34.94% down from last year.
  • As of Q4 2024, Ptc Therapeutics' Accumulated Depreciation & Amortization stood at $33.4 million, which was down 34.94% from $51.3 million recorded in Q4 2023.
  • In the past 5 years, Ptc Therapeutics' Accumulated Depreciation & Amortization registered a high of $51.3 million during Q4 2023, and its lowest value of $18.1 million during Q4 2020.
  • For the 3-year period, Ptc Therapeutics' Accumulated Depreciation & Amortization averaged around $40.7 million, with its median value being $37.4 million (2022).
  • Per our database at Business Quant, Ptc Therapeutics' Accumulated Depreciation & Amortization skyrocketed by 52.76% in 2020 and then tumbled by 34.94% in 2024.
  • Quarterly analysis of 5 years shows Ptc Therapeutics' Accumulated Depreciation & Amortization stood at $18.1 million in 2020, then surged by 50.44% to $27.2 million in 2021, then soared by 37.52% to $37.4 million in 2022, then soared by 37.21% to $51.3 million in 2023, then slumped by 34.94% to $33.4 million in 2024.
  • Its Accumulated Depreciation & Amortization stands at $33.4 million for Q4 2024, versus $51.3 million for Q4 2023 and $37.4 million for Q4 2022.